Experienced in Infant Hearing Loss

Marisa M. Pinhata-Mussi

Bandeirantes Avenue 3900, 
Ribeirao Preto, SP, BR 
Experienced in Infant Hearing Loss
Bandeirantes Avenue 3900, 
Ribeirao Preto, SP, BR 
OverviewLocationsClinical Research

Overview

Marisa Pinhata-Mussi practices in Ribeirao Preto, Brazil. Ms. Pinhata-Mussi is rated as an Experienced expert by MediFind in the treatment of Infant Hearing Loss. Her top areas of expertise are Congenital Cytomegalovirus, Cytomegalovirus Infection, Cytomegalic Inclusion Disease, and Zika Virus Disease.

Her clinical research consists of co-authoring 78 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Infant Hearing Loss.

Gender
Female

Locations

Bandeirantes Avenue 3900, Ribeirao Preto, SP, Brazil
Other Locations
Otorhinolaryngology And Head And Neck Surgery, Sao Paulo, SP, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Enrollment Status: Completed
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Dolutegravir, ABC/DTG/3TC
Study Phase: Phase 3
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Enrollment Status: Terminated
Publish Date: April 20, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

77 Total Publications

Motor dysfunction in preschool children exposed to zika virus during pregnancy and normocephalic at birth: Developmental Coordination Disorder and Minimal Neurological Dysfunction.
Motor dysfunction in preschool children exposed to zika virus during pregnancy and normocephalic at birth: Developmental Coordination Disorder and Minimal Neurological Dysfunction.
Journal: Early human development
Published: December 10, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pinhata-Mussi's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile